Patent application EP17177183A (EP), filed 2017-06-21
Publication number: EP3260120A1
Title: PHARMACOLOGICAL ADJUVANTS FOR THERMAL ABLATION OF CANCER
Abstract: The present invention relates to the use of proton pomp inhibitors in thermal ablation of cancer, and in particular to the use of proton pomp inhibitors encapsulated in liposomes. Furthermore, the invention relates to proton pomp inhibitors in acid solution, encapsulated in liposomes coated with polyethylene glycol or polysaccharides like dextran, and to pharmaceutical formulations containing them.
IPC codes: A61K  31/  4439            A I
A61K   9/   127            A I
A61P  35/    00            A I
Claims: number: 1
text: A proton pump inhibitor for use in a tumour thermoablation method.
number: 2
text: A proton pump inhibitor for use according to claim 1, wherein the proton pump inhibitor is selected from the group consisting of omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole.
number: 3
text: A proton pump inhibitor for use according to claim 2, wherein the proton pump inhibitor is omeprazole.
number: 4
text: A proton pump inhibitor for use according to any one of claims 1-3, wherein the inhibitor is encapsulated in a liposome.
number: 5
text: A proton pump inhibitor for use according to claim 4, wherein the inhibitor is dissolved in an acidic solution.
number: 6
text: A proton pump inhibitor for use according to claim 4 or 5, wherein the liposome is coated with polyethylene glycol or a polysaccharide.
number: 7
text: A proton pump inhibitor for use according to claim 6, wherein the liposome is coated with polyethylene glycol or dextran.
number: 8
text: A proton pump inhibitor for use according to claim 4 or 5, wherein the liposome is thermosensitive.
number: 9
text: A proton pump inhibitor encapsulated in a liposome wherein the liposome is coated with polyethylene glycol or a polysaccharide.
number: 10
text: The proton pump inhibitor encapsulated in a liposome according to claim 9, wherein the liposome is coated with polyethylene glycol or dextran.
number: 11
text: The proton pump inhibitor according to claim 9 or 10, wherein the proton pump inhibitor is selected from the group consisting of omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole.
number: 12
text: The proton pump inhibitor according to claim 11, wherein the proton pump inhibitor is omeprazole.
number: 13
text: The proton pump inhibitor according to any one of claims 9 to 12, wherein the inhibitor is dissolved in an acidic solution.
number: 14
text: The proton pump inhibitor according to any one of claims 9 to 13 wherein the liposome comprises hydrogenated phosphatidylcholine, distearoyl phosphatidylethanolamine pegylated with polyethylene glycol 2000 and cholesterol in a weight ratio of 60:20:20, wherein the weight ratio between lipids and inhibitor is 95:5.
number: 15
text: The proton pump inhibitor according to any one of claims 9 to 14 for use as adjuvant in chemotherapy.
number: 16
text: A pharmaceutical formulation comprising a proton pump inhibitor according to any one of claims 9 to 14 and a suitable carrier and/or excipient.
Office action: search_report, dated 2017-12-27
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: US5013556A
ref_type: patent
severity: background
ref_id: - AHMED M, CHERN PHYS LIPIDS, vol. 165, 2012, pages 424 - 37
ref_type: npl
severity: background
ref_id: - CHU KF, NAT REV CANCER, vol. 14, 2014, pages 199 - 208
ref_type: npl
severity: background
ref_id: - PAIN D, J. BIOSCI, vol. 6, 1984, pages 811 - 6
ref_type: npl
severity: background
ref_id: - NING S, SOFT MATTER, vol. 7, 2011, pages 9394 - 401
ref_type: npl
severity: background
ref_id: - KONING GA, PHARM RES, vol. 27, 2010, pages 1750 - 4
ref_type: npl
severity: background
ref_id: - LANDON CD, OPEN NANOMED J, vol. 3, 2011, pages 38 - 64
ref_type: npl
severity: background
ref_id: - MANZOOR AA, CANCER RES, vol. 72, 2012, pages 5566 - 75
ref_type: npl
severity: background
ref_id: - KNEIDL B, INT J NANOMEDICINE, vol. 9, 2014, pages 4387 - 98
ref_type: npl
severity: background
ref_id: - LENCIONI R, PRESENTATION AT THE EUROPEAN CONFERENCE ON INTERVENTIONAL ONCOLOGY (ECIO), BUDAPEST (HUNGARY, 19 June 2013 (2013-06-19)
ref_type: npl
severity: background
ref_id: - POON RT, PRESENTATION AT THE WORLD CONFERENCE ON INTERVENTIONAL ONCOLOGY, 16 May 2013 (2013-05-16)
ref_type: npl
severity: background
ref_id: - FINN RS, PRESENTATION AT THE 8TH INTERNATIONAL LIVER CANCER ASSOCIATION (ILCA) ANNUAL CONFERENCE, KYOTO (JAPAN, 5 September 2014 (2014-09-05)
ref_type: npl
severity: background
ref_id: - BARONZIO GF: "Hyperthermia in cancer treatment: a primer", 2006, LANDES-SPRINGER PUBLISHERS, pages: 67 - 91
ref_type: npl
severity: background
ref_id: - SONG CW: "Cancer drug resistance", 2006, HUMANA PRESS, pages: 21 - 42
ref_type: npl
severity: background
ref_id: - JONES EL: "Principles and practice of radiation oncology", 2008, LIPPINCOTT WILLIAMS & WILKINS, pages: 637 - 68
ref_type: npl
severity: background
ref_id: - VIGLIANTI BL; HOLLAND-FREI ET AL.: "cancer medicine", 2010, PEOPLE'S MEDICAL PUBLISHING HOUSE-USA, pages: 528 - 40
ref_type: npl
severity: background
ref_id: - HELANDER HF, SCAND J GASTROENTEROL, vol. 20, no. 108, 1985, pages 95 - 104
ref_type: npl
severity: background
ref_id: - OLBE L, NAT REV DRUG DISCOV, vol. 2, 2003, pages 132 - 9
ref_type: npl
severity: background
ref_id: - DE MILITO A, CURR PHARM DES, vol. 18, 2012, pages 1395 - 406
ref_type: npl
severity: background
ref_id: - SPUGNINI EP, J EXP CLIN CANCER RES, vol. 29, 2010, pages 44
ref_type: npl
severity: background
ref_id: - FAIS S, J INTERN MED, vol. 267, 2010, pages 515 - 25
ref_type: npl
severity: background
ref_id: - PARKS SK, NAT REV CANCER, vol. 13, 2013, pages 611 - 23
ref_type: npl
severity: background
ref_id: - FAIS S, CANCER METASTASIS REV, vol. 33, 2014, pages 1095 - 108
ref_type: npl
severity: background
ref_id: - MATUSZCAK C, CAN CELL MICROENVIRON, vol. 2, 2015, pages e667
ref_type: npl
severity: background
ref_id: - WALSH M, J EXP CLIN CANCER RES, vol. 34, 2015, pages 93
ref_type: npl
severity: background
ref_id: - WANG BY, J EXP CLIN CANCER RES, vol. 34, 2015, pages 85
ref_type: npl
severity: background
ref_id: WO2017048860A1
ref_type: patent
severity: background
ref_id: WO2005077365A2
ref_type: patent
severity: background
ref_id: EP2548555A1
ref_type: patent
severity: background
ref_id: US2009227633A1
ref_type: patent
severity: background
ref_id: CN103127003B
ref_type: patent
severity: background
ref_id: CN104546718A
ref_type: patent
severity: background
ref_id: - OVERHOLT B F ET AL: "Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients", GASTROINTESTINAL ENDOSCOPY, ELSEVIER, NL, vol. 49, no. 1, 1 January 1999 (1999-01-01), pages 1 - 7, XP027500214, ISSN: 0016-5107, [retrieved on 19990101], DOI: 10.1016/S0016-5107(99)70437-2
ref_type: npl
severity: background
ref_id: - BOAS F EDWARD ET AL: "Adjuvant Medications That Improve Survival after Locoregional Therapy", JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, vol. 28, no. 7, 1999, pages 971, XP085094602, ISSN: 1051-0443, DOI: 10.1016/J.JVIR.2017.04.016
ref_type: npl
severity: background
ref_id: - TACKER J R ET AL: "DELIVERY OF ANTI TUMOR DRUG TO BLADDER CANCER BY USE OF PHASE TRANSITION LIPOSOMES AND HYPER THERMIA", JOURNAL OF UROLOGY, vol. 127, no. 6, 1982, pages 1211 - 1214, XP002769669, ISSN: 0022-5347
ref_type: npl
severity: background
ref_id: WO2005077365
ref_type: patent
severity: background
ref_id: US2009227633
ref_type: patent
severity: background
ref_id: EP2548555
ref_type: patent
severity: background
ref_id: CN103127003B
ref_type: patent
severity: background
ref_id: CN104546718
ref_type: patent
severity: background
ref_id: WO2017048860
ref_type: patent
severity: novelty_destroying
ref_id: - OVERHOLT B F ET AL, "Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients", GASTROINTESTINAL ENDOSCOPY, ELSEVIER, NL, vol. 49, no. 1, doi:10.1016/S0016-5107(99)70437-2, ISSN 0016-5107, (19990101), pages 1 - 7, (19990101), XP027500214 [X] 1-3 * abstract *
ref_type: npl
severity: novelty_destroying
ref_id: - BOAS F EDWARD ET AL, "Adjuvant Medications That Improve Survival after Locoregional Therapy", JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, (1999), vol. 28, no. 7, doi:10.1016/J.JVIR.2017.04.016, ISSN 1051-0443, page 971, XP085094602 [X] 1-3 * abstract * * tables 1,2 * * page  971  - page  973, column  l *
ref_type: npl
severity: novelty_destroying
ref_id: - TACKER J R ET AL, "DELIVERY OF ANTI TUMOR DRUG TO BLADDER CANCER BY USE OF PHASE TRANSITION LIPOSOMES AND HYPER THERMIA", JOURNAL OF UROLOGY, (1982), vol. 127, no. 6, ISSN 0022-5347, pages 1211 - 1214, XP002769669 [X] 9-12,15,16 * abstract * [I] 1-8,13,14
ref_type: npl
severity: novelty_destroying
Final disposition: pending (2017-12-27)